Events & Seminars > Event Details


Room 205, Mechanical Engineering Building

Redefining druggability using chemoproteomic platforms


Professor Dan Nomura
University of California, Berkeley

Hosted by: Professor Ken Hsu

The Nomura Research Group is focused on developing and applying chemoproteomic platforms to drug the undruggable proteome to develop next-generation disease therapies. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable” or difficult to target with small-molecules. Our research group addresses this challenge by developing chemoproteomic platforms to discover and pharmacologically target unique and novel therapeutic druggable hotspots for disease therapy.  We currently have four major research directions. Our first research area focuses on coupling phenotypic screening of fragment-based covalent ligand libraries with chemoproteomic platforms to rapidly discover novel druggable hotspots, targets, and small-molecule leads for disease therapy. Our second research area focuses on covalent ligand discovery against druggable hotspots targeted by covalently-acting natural products that show therapeutic activity using chemoproteomic platforms to discover new therapeutic targets and synthetically tractable therapies for cancer. Our third research area focuses on advancing chemoproteomic technologies to map and pharmacologically target druggable hotspots for targeted protein degradation. Our fourth research area focuses on using chemoproteomic platforms to map on and off-targets of environmental and pharmaceutical chemicals towards discovering new toxicological mechanisms. Our fifth research area focuses on using chemoproteomic and metabolomic platforms to discover unique and novel metabolic drivers of cancer. The talk will focus on examples of how we have used our chemoproteomic platforms to identify new leads, targets, and druggable hotspots for disease therapy.


Dan Nomura is an associate professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an associate adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology at UC Berkeley with Professor John Casida and was a postdoctoral fellow at The Scripps Research Institute with Professor Ben Cravatt before returning to Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, and the Department of Defense Breakthroughs Award. The Nomura Research Group is focused on mapping drivers of human disease through the development and application of chemical biology approaches including chemoproteomic and metabolomic platforms.